Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 19, 2021

Lilly begins enrolment in Phase IV trial of Emgality for migraine prevention

The trial will enrol nearly 700 adult subjects across the US and assess them for up to six months.

Eli Lilly and Company has commenced subject enrolment in Phase IV CHALLENGE-MIG clinical trial Emgality (galcanezumab-gnlm) injection as a preventive therapy for episodic migraine in adult patients.

A monoclonal antibody, Emgality specifically attaches to calcitonin gene-related peptide (CGRP).

The drug is approved by the US Food and Drug Administration (FDA) as preventive migraine therapy for adults.

In June 2021, the company announced plans to study Emgality against oral Nurtec ODT in a Phase IV head-to-head study as a preventive migraine treatment.

This double-blind, randomised, placebo-controlled trial will compare the efficacy and safety of a once-monthly injectable dose of Emgality to oral doses of Nurtec ODT (rimegepant) given on alternative days.

It will enrol nearly 700 adult subjects across the US who will be analysed for a duration of up to six months.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

CHALLENGE-MIG is claimed to be the first-ever trial to compare two CGRP therapies as episodic migraine prevention treatment.

The percentage of subjects with a reduction of ≥50% in monthly migraine headache days from baseline throughout the three-month double-blind treatment duration will be the trial’s primary goal.

A ≥75% decline and complete reduction from baseline in monthly migraine headache days, advances in the migraine-specific quality of life, and migraine disability assessment will be the secondary goals of the trial.

Eli Lilly and Company senior vice-president Anne White said: “Lilly has been deeply committed to neuroscience research across a spectrum of diseases for over 30 years.

“We believe patients should expect more and get more from medications that can help prevent migraine. Therefore, we look forward to sharing the findings from our Emgality versus Nurtec ODT head-to-head trial.”

In June 2019, the FDA approved Emgality for the treatment of episodic cluster headache in adults

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU